Regeneron Pharmaceuticals holds the cleaner structural position, with profitability as the main driver and growth adding further support. Sanofi still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, Regeneron Pharmaceuticals is in better shape — its trend is intact while Sanofi's trend has broken down. That puts structure and market broadly in agreement — Regeneron Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels.
The clearest score difference appears in profitability. Regeneron Pharmaceuticals, Inc. leads by 15 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
This level of similarity points to a meaningful structural match, though not a tight one.
Most of the shared profile comes through revenue stability and margin trend.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The two profiles are relatively close, but the price setup still leans toward Regeneron Pharmaceuticals, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The profitability lead is mainly driven by a 8.9-point operating margin advantage.
Earnings growth also leans the other way, which keeps the score lead from reading as a full growth sweep.
Profitability settles the comparison, while pricing and growth keep the broader setup from looking fully aligned.
Break down the REGN vs SAN.PA comparison across all dimensions with the full interactive tool.
Explore how REGN and SAN.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.